Skip to main content

Kate Smith

Authored Items
New Data on Ixazomib Maintenance Support Long-Term Oral Therapy in Patients with Myeloma
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Weekly Carfilzomib Safe and Effective
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Monoclonal Antibodies Poised to Be “Blockbusters” in Myeloma
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Financial Toxicity Impacts Treatment Adherence
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
The Hematology Pipeline Is Abundant
Wayne Kuznar, Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in FDA Approvals
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Last modified: April 23, 2015